- Survival in acute lymphoblastic leukemia (ALL) worsens with increasing age, and OS is poorer in adults with secondary ALL than in those with de novo ALL.
Why this matters
- Although improved chemotherapy regimens and novel chemotherapy for ALL have boosted complete remission rates, secondary ALL remains common.
- Retrospective analysis of 8305 patients with ALL (de novo: 7454; secondary: 851) undergoing chemotherapy, identified in the Surveillance, Epidemiology, and End Results database.
- Funding: None disclosed.
- Women with ALL had a lower mortality risk than men: HR, 0.93 (P<.01>
- Mortality in black patients was higher than that in whites: HR, 1.29 (P<.001>
- For both ALL groups, compared with younger patients, mortality risk (HRs) was much higher in patients ages:
- 45-75 years: 1.82 (P<.001 and>
- ≥75 years: 3.85 (P<.001>
- Individualized chemotherapy data were not available for analysis.